Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability.

Published

Journal Article

While aspirin is generally effective for prevention of cardiovascular disease, considerable variation in drug response exists, resulting in some individuals displaying high on-treatment platelet reactivity. We used pharmacometabolomics to define pathways implicated in variation of response to treatment. We profiled serum samples from healthy subjects pre- and postaspirin (14 days, 81 mg/day) using mass spectrometry. We established a strong signature of aspirin exposure independent of response (15/34 metabolites changed). In our discovery (N = 80) and replication (N = 125) cohorts, higher serotonin levels pre- and postaspirin correlated with high, postaspirin, collagen-induced platelet aggregation. In a third cohort, platelets from subjects with the highest levels of serotonin preaspirin retained higher reactivity after incubation with aspirin than platelets from subjects with the lowest serotonin levels preaspirin (72 ± 8 vs. 61 ± 11%, P = 0.02, N = 20). Finally, ex vivo, serotonin strongly increased platelet reactivity after platelet incubation with aspirin (+20%, P = 4.9 × 10(-4), N = 12). These results suggest that serotonin is implicated in aspirin response variability.

Full Text

Duke Authors

Cited Authors

  • Ellero-Simatos, S; Lewis, JP; Georgiades, A; Yerges-Armstrong, LM; Beitelshees, AL; Horenstein, RB; Dane, A; Harms, AC; Ramaker, R; Vreeken, RJ; Perry, CG; Zhu, H; Sànchez, CL; Kuhn, C; Ortel, TL; Shuldiner, AR; Hankemeier, T; Kaddurah-Daouk, R

Published Date

  • July 16, 2014

Published In

Volume / Issue

  • 3 /

Start / End Page

  • e125 -

PubMed ID

  • 25029353

Pubmed Central ID

  • 25029353

Electronic International Standard Serial Number (EISSN)

  • 2163-8306

International Standard Serial Number (ISSN)

  • 2163-8306

Digital Object Identifier (DOI)

  • 10.1038/psp.2014.22

Language

  • eng